Apixaban vs enoxaparin to prevent blood clots after spinal cord injury
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Injuries & trauma clinical trials.
This trial studies whether apixaban works as well as enoxaparin to prevent dangerous blood clots after spinal cord injury. If you qualify, you would take one of these medicines to lower clot risk during the recovery period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a spinal cord injury (from trauma or non-trauma).
- You can speak Hebrew well enough for the study.
- You do not have a reason you cannot take blood thinners (anticoagulants).
- You are not already taking any other blood thinner medication at the same time.
- You are not pregnant or breastfeeding.
- Your kidneys and liver are healthy enough for these medicines, and you have no bleeding that needs urgent treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two blood-thinning medicines, apixaban and enoxaparin, to see which works better at preventing dangerous blood clots after delivery. It is for women who have certain risk factors that make them more likely to get a clot.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
This trial tests whether a medication called apixaban (a blood thinner) can safely prevent blood clots after abdominal or pelvic surgery. It is for people who have a moderate risk of clots and bleeding, and who are not taking other blood thinners.
This trial tests if a higher dose of a blood thinner (enoxaparin) works better than the standard dose to prevent dangerous blood clots in the legs or lungs after a severe injury. It is for adults in the intensive care unit who are expected to stay more than 48 hours.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.
Hear when a new Spinal Cord Injuries trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.